Ketamine to treat depression trial
Black Dog Institute researchers have demonstrated the enormous potential of ketamine as a new treatment for major depression.
Chief Investigator: Professor Colleen Loo
Whilst ketamine is approved for use in anaesthesia, it has not received approval for use in depression. This is because there are still significant gaps in our knowledge about dosage levels, treatment protocols and the effectiveness and safety of longterm use. Professor Colleen Loo and her team have done some pioneering work in answering these important questions.
We are pleased to announce that the NHMRC has provided funding to establish a national clinical trial into ketamine. This study commenced in mid-2016 with trial locations based in Sydney, Melbourne, Noble Park (VIC), Adelaide, Perth and Dunedin (NZ).
We are actively recruiting participants for this study in Sydney, Adelaide, Melbourne and Noble Park (VIC). For more information, or to be screened for our study at one of these locations, please email your name, phone number and address to your preferred trial site:
- Black Dog Institute/UNSW, Sydney (NSW): email@example.com [phone: (02) 9382 9509]
- Professor Marie Bashir Centre/USyd, Sydney (NSW): firstname.lastname@example.org [phone: (02) 9515 1439]
- Royal Adelaide Hospital, Adelaide (SA): email@example.com [phone: (08) 8313 7676]
- Monash Alfred Psychiatry Research Centre, Melbourne (VIC): firstname.lastname@example.org [phone: (03) 9076 6592]
- South Eastern Private Hospital, Noble Park (VIC): Ket.Study@healthecare.com.au
- Gold Coast University Hospital, Gold Coast, (QLD): KetamineTrialGoldCoast@health.qld.gov.au
Please note, you will most likely receive a faster reply emailing rather than calling on the phone.
Recruitment is not yet open in Perth or Dunedin. If you would like to register your interest in attending the trial at either of these sites, please email your name, phone number and address to the site coordinator of your preferred location: